RET and spindle cell neoplasm: The patient's disease was managed through sequential targeted therapies, including combination therapy with third-generation inhibitors targeting RET and NTRK.<h4>Conclusion</h4>Our findings suggest that distinct <i>RET</i> fusion partners significantly contribute to the clinical heterogeneity of <i>RET</i>-rearranged spindle cell tumors, likely through differential kinase activity.